MERCURY STREET MEDICAL GROUP, PLLC
- Type
- Non-covered entity
- Where
- BUTTE, MT
- Received
- $970,476 in 836 records, 2019 to 2025 ($0 general, $970,476 research)
- Source
- CMS Open Payments search ↗
On this site
- Federal award recipient: MERCURY STREET MEDICAL GROUP, PLLC Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | Research payment | 5 | $34,904 |
| 2024 | Research payment | 152 | $47,403 |
| 2023 | Research payment | 22 | $484,386 |
| 2022 | Research payment | 297 | $102,435 |
| 2021 | Research payment | 223 | $103,465 |
| 2020 | Research payment | 62 | $190,962 |
| 2019 | Research payment | 75 | $6,919 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Novo Nordisk AS | 829 | $474,839 | 2019–2025 |
| AstraZeneca Pharmaceuticals LP | 2 | $423,864 | 2023 |
| VIVUS LLC | 2 | $34,500 | 2022–2023 |
| Novartis Pharmaceuticals Corporation | 1 | $24,272 | 2025 |
| SCYNEXIS, Inc. | 1 | $11,500 | 2022 |
| Melinta Therapeutics, LLC | 1 | $1,500 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 836 | $970,476 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-11-05 | Novo Nordisk AS | $1,000 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4801 | 2025 |
| 2025-11-05 | Novo Nordisk AS | $500 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4801 | 2025 |
| 2025-10-27 | Novartis Pharmaceuticals Corporation | $24,272 | Research payment | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-07-21 | Novo Nordisk AS | $5,036 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4801 | 2025 |
| 2025-02-21 | Novo Nordisk AS | $4,095 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4801 | 2025 |
| 2024-11-20 | Novo Nordisk AS | $3,905 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-10-31 | Novo Nordisk AS | $4,897 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-10-31 | Novo Nordisk AS | $219 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-10-31 | Novo Nordisk AS | $219 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-09-30 | Novo Nordisk AS | $219 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-09-30 | Novo Nordisk AS | $219 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-09-22 | Novo Nordisk AS | $594 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-09-20 | Novo Nordisk AS | $2,234 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-23 | Novo Nordisk AS | $3,767 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-08-22 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-07-22 | Novo Nordisk AS | $7,630 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-05-31 | Novo Nordisk AS | $4,495 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-04-30 | Novo Nordisk AS | $3,631 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-04-16 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-04-12 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-29 | Novo Nordisk AS | $6,865 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $120 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-03-27 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-31 | Novo Nordisk AS | $219 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-31 | Novo Nordisk AS | $219 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-31 | Novo Nordisk AS | $219 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $160 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $14 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $14 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $14 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $14 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $14 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $14 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $14 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $14 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $14 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $14 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $14 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $14 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-25 | Novo Nordisk AS | $14 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2024-01-02 | Novo Nordisk AS | $891 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2024 |
| 2023-12-31 | AstraZeneca Pharmaceuticals LP | $34,976 | Research payment | In-kind items and services | A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and | 2023 | |
| 2023-12-18 | Novo Nordisk AS | $12,695 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2023 |
| 2023-12-18 | Novo Nordisk AS | $1,000 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2023 |
| 2023-11-27 | Novo Nordisk AS | $3,804 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4801 | 2023 |
| 2023-10-13 | VIVUS LLC | $7,600 | Research payment | Cash or cash equivalent | QSYMIA Drug, ENDOCRINOLOGY | A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject | 2023 |
| 2023-09-22 | Novo Nordisk AS | $975 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2023 |
| 2023-08-18 | Novo Nordisk AS | $3,437 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2023 |
| 2023-07-26 | Novo Nordisk AS | $1,787 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2023 |
| 2023-07-19 | AstraZeneca Pharmaceuticals LP | $388,887 | Research payment | Cash or cash equivalent | A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and | 2023 | |
| 2023-07-03 | Novo Nordisk AS | $7,741 | Research payment | Cash or cash equivalent | Rybelsus Drug, Diabetes | NN9924-4635 | 2023 |
| 2023-06-23 | Novo Nordisk AS | $4,011 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2023 |
| 2023-05-26 | Novo Nordisk AS | $4,719 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2023 |
| 2023-05-26 | Novo Nordisk AS | $3,432 | Research payment | Cash or cash equivalent | Rybelsus Drug, Diabetes | NN9924-4635 | 2023 |
| 2023-05-12 | Novo Nordisk AS | $20 | Research payment | In-kind items and services | Wegovy Drug, Obesity | EX9536-4388 | 2023 |
| 2023-04-24 | Novo Nordisk AS | $2,522 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2023 |
| 2023-03-24 | Novo Nordisk AS | $270 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2023 |
| 2023-02-28 | Novo Nordisk AS | $70 | Research payment | In-kind items and services | Rybelsus Drug, Diabetes | NN9924-4635 | 2023 |
| 2023-02-22 | Novo Nordisk AS | $1,238 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2023 |
| 2023-01-31 | Novo Nordisk AS | $70 | Research payment | In-kind items and services | Rybelsus Drug, Diabetes | NN9924-4635 | 2023 |
| 2023-01-25 | Novo Nordisk AS | $4,417 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2023 |
| 2023-01-25 | Novo Nordisk AS | $702 | Research payment | Cash or cash equivalent | Rybelsus Drug, Diabetes | NN9924-4635 | 2023 |
| 2023-01-23 | Novo Nordisk AS | $5 | Research payment | In-kind items and services | Wegovy Drug, Obesity | EX9536-4388 | 2023 |
| 2022-12-21 | Novo Nordisk AS | $2,680 | Research payment | Cash or cash equivalent | Rybelsus Drug, Diabetes | NN9924-4635 | 2022 |
| 2022-12-21 | Novo Nordisk AS | $664 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2022 |
| 2022-12-02 | Novo Nordisk AS | $1,859 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2022 |
| 2022-11-30 | Novo Nordisk AS | $3,141 | Research payment | Cash or cash equivalent | Rybelsus Drug, Diabetes | NN9924-4635 | 2022 |
| 2022-11-07 | SCYNEXIS, Inc. | $11,500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Inva | 2022 | |
| 2022-10-31 | Novo Nordisk AS | $3,500 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4801 | 2022 |
| 2022-10-07 | VIVUS LLC | $26,900 | Research payment | Cash or cash equivalent | QSYMIA Drug, ENDOCRINOLOGY | A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject | 2022 |
| 2022-09-30 | Novo Nordisk AS | $1,114 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2022 |
| 2022-09-28 | Novo Nordisk AS | $1,801 | Research payment | Cash or cash equivalent | Rybelsus Drug, Diabetes | NN9924-4635 | 2022 |
| 2022-08-30 | Novo Nordisk AS | $40 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2022 |
| 2022-08-30 | Novo Nordisk AS | $39 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2022 |
| 2022-08-30 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2022 |
| 2022-08-30 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2022 |
| 2022-08-30 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2022 |
| 2022-08-30 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2022 |
| 2022-08-30 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2022 |
| 2022-08-30 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2022 |
| 2022-08-30 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2022 |
| 2022-08-30 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2022 |
| 2022-08-30 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2022 |
| 2022-08-30 | Novo Nordisk AS | $11 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4801 | 2022 |
The latest 200 records of 836.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Butte-Silver Bow, MT, county Silver Bow County, MT, state Montana; placed by its city name.
| Measure | Place (city or town) Butte-Silver Bow, MT | County Silver Bow County, MT | State Montana |
|---|---|---|---|
| Population B01003 | 35,052 | 35,785 | 1,116,875 |
| Population, 2020 census P1 | 34,494 | 35,133 | 1,084,225 |
| Median age B01002 | 40.6 | 40.5 | 40.4 |
| Under 18 B01001 | 20.2% | 20.2% | 21.0% |
| 65 and over B01001 | 19.5% | 19.5% | 20.1% |
| Households B11001 | 15,127 | 15,419 | 458,859 |
| Foreign born B05002 | 1.2% | 1.2% | 2.3% |
| Median household income B19013 | $61,857 | $61,754 | $72,509 |
| Median family income B19113 | $82,625 | $82,641 | $92,794 |
| Per capita income B19301 | $36,035 | $35,951 | $41,711 |
| Poverty rate B17001 | 14.8% | 14.8% | 11.5% |
| Unemployment rate B23025 | 4.0% | 4.1% | 3.6% |
| Civilian labor force B23025 | 17,262 | 17,630 | 568,568 |
| Mean commute (minutes) B08013 | 16.9 | 16.9 | 19.1 |
| Bachelor's degree or higher B15003 | 28.1% | 28.0% | 35.2% |
| Housing units B25001 | 17,158 | 17,499 | 528,419 |
| Owner-occupied B25003 | 70.7% | 70.8% | 69.2% |
| Renters B25003 | 29.3% | 29.2% | 30.8% |
| Median home value B25077 | $257,800 | $255,200 | $375,800 |
| Median gross rent B25064 | $856 | $863 | $1,081 |
| White, not Hispanic B03002 | 89.0% | 89.1% | 83.6% |
| Black B03002 | 0.1% | 0.1% | 0.4% |
| Hispanic or Latino B03002 | 4.7% | 4.6% | 4.6% |
| Asian B03002 | 0.4% | 0.4% | 0.8% |
| American Indian and Alaska Native B03002 | 1.4% | 1.4% | 5.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Butte-Silver Bow, MT.
Comments